I. Katay

Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).

V. Diehl, H. Tesch, A. Engert, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

rosette-inhibiting factor L428 cells derived from Hodgkin's disease produce E

V. Diehl, U. Wirnitzer, C. Kalle, 2011 .

Phase II Trial of Idarubicin, Fludarabine, Cytosine Arabinoside and Filgrastim (G-CSF) for Treatment of Refractory, Relapsed, and Secondary Acute Myeloid Leukemia

V. Diehl, A. Glasmacher, P. Staib, 1997 .

Use of granulocyte colony-stimulating factor (filgrastim) in the treatment of non-cytotoxic drug-induced agranulocytosis.

V. Diehl, C. Scheid, A. Josting, 1995, European journal of medical research.

L428 cells derived from Hodgkin's disease produce E rosette-inhibiting factor.

C. von Kalle, V. Diehl, U. Wirnitzer, 1990, Blood.

The combination of sorafenib and everolimus in patients with solid tumors: Results of a phase I study.

U. Fuhr, N. Harbeck, J. Wolf, 2011, Journal of Clinical Oncology.